瑞康医药集团股份有限公司关于回购公司股份的进展公告

Core Viewpoint - 瑞康医药集团股份有限公司 has initiated a share repurchase plan to enhance employee stock ownership and improve shareholder value, with a total repurchase budget between RMB 100 million and RMB 200 million [2][3]. Group 1: Share Repurchase Plan - The company approved a share repurchase plan using bank loans and its own funds, with a maximum repurchase price of RMB 4.5 per share [2]. - The total amount allocated for the repurchase is not less than RMB 100 million and not more than RMB 200 million [2]. - The repurchase period is set for 12 months from the date of board approval [2]. Group 2: Progress of Share Repurchase - As of July 31, 2025, the company has repurchased 20.446517 million shares, accounting for 1.36% of the total share capital [3]. - The highest transaction price during the repurchase was RMB 3.08 per share, while the lowest was RMB 2.75 per share, with a total transaction amount of RMB 60.3963 million (excluding transaction fees) [3]. Group 3: Compliance and Regulations - The company has adhered to relevant regulations regarding the timing and pricing of the share repurchase, ensuring compliance with the Shenzhen Stock Exchange guidelines [4][5]. - The company will continue to implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by law [6][7].